Exhibit 10.33
CONFIDENTIAL TREATMENT
REQUESTED
CONFIDENTIAL TREATMENT REQUESTED: INFORMATION FOR
WHICH CONFIDENTIAL TREATMENT HAS
BEEN REQUESTED IS OMITTED AND IS NOTED AS FOLLOWS **REDACTED**.
AN
UNREDACTED VERSION OF THIS DOCUMENT HAS BEEN FILED SEPARATELY WITH
THE SECURITIES AND
EXCHANGE COMMISSION.
AMENDMENT NO. 2
AMENDMENT TO
LICENSE AND COLLABORATION
AGREEMENT
THIS
AMENDMENT TO LICENSE AND COLLABORATION AGREEMENT
(this “ Amendment
”), is entered into this 25 th day of
June 2007 (the “ Effective Date ”) by and
between Santaris Pharma A/S , a Danish corporation having
its principal place of business at Hørsholm, Denmark
(“ Santaris ”), and Enzon Pharmaceuticals,
Inc. , a Delaware corporation having its principal place of
business at Bridgewater, New Jersey 08807 (“ Enzon
”). Santaris and Enzon may be referred to herein individually
as a “ Party ” or collectively, as the “
Parties ”.
BACKGROUND
WHEREAS, Enzon and Santaris
entered into the License and Collaboration Agreement dated July 26,
2006 (the “ Agreement ”); and
WHEREAS, Enzon and Santaris
desire to amend and restate certain provisions of the
Agreement.
NOW, THEREFORE, in consideration
of the covenants and obligations expressed herein and intending to
be legally bound, and otherwise bound by proper and reasonable
conduct, the Parties agree as f
